Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.73 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.73 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.73 |
| ▸ | POLB | P06746 | 2/20 | 0.66 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.66 |
| ▸ | HPGD | P15428 | 1/20 | 0.66 |
| ▸ | RAB9A | P51151 | 1/20 | 0.66 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.66 |
| ▸ | CHEK2 | O96017 | 16/20 | 0.65 |
| ▸ | PKN1 | Q16512 | 1/20 | 0.58 |
| ▸ | PKN2 | Q16513 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8262964 | 0.87 | HSP90AA1 (0.55) | HSP90AA1ESR2TDP1POLBALDH1A1 | |
| SCHEMBL6113137 | 0.85 | HSP90AA1 (0.76) | HSP90AA1ESR2TDP1POLBALDH1A1 | |
| SCHEMBL1758956 | 0.85 | TDP1 (1.00) | HSP90AA1ESR2TDP1POLBALDH1A1 | |
| SCHEMBL29924530 | 0.85 | TDP1 (1.00) | HSP90AA1ESR2TDP1POLBALDH1A1 | |
| Hydrochloric Acid SCHEMBL7331913 | 0.83 | TDP1 (0.97) | HSP90AA1ESR2TDP1POLBALDH1A1 | |
| SCHEMBL7362185 | 0.83 | F10 (0.65) | HSP90AA1ESR2TDP1POLBALDH1A1 | |
| Carbamic Acid SCHEMBL29258949 | 0.82 | ALDH1A1 (0.92) | HSP90AA1ESR2TDP1POLBALDH1A1 | |
| SCHEMBL1805538 | 0.82 | HSP90AA1 (0.62) | HSP90AA1ESR2TDP1POLBALDH1A1 | |
| SCHEMBL1805540 | 0.82 | HSP90AA1 (0.62) | HSP90AA1ESR2TDP1POLBALDH1A1 | |
| SCHEMBL3416768 | 0.81 | CHEK2 (0.61) | CHEK2PKN1PKN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4284370-A1 | COMBINATION THERAPIES | Mirati Therapeutics, Inc. (US) | 2023-12-06 | — | — | EP | disclosed |
| WO-2022165142-A1 | COMBINATION THERAPIES | Mirati Therapeutics, Inc. (US) | 2022-08-04 | — | — | WO | disclosed |
| EP-2970158-B1 | ALKYL-HETEROARYL SUBSTITUTED QUINONE DERIVATIVES FOR TREATMENT OF OXIDATIVE STRESS DISORDERS | BIOELECTRON TECH CORP (US) | 2019-02-20 | — | — | EP | disclosed |
| US-20160024085-A1 | ALKYL-HETEROARYL SUBSTITUTED QUINONE DERIVATIVES FOR TREATMENT OF OXIDATIVE STRESS DISORDERS | PTC THERAPEUTICS, INC. | 2016-01-28 | — | — | US | disclosed |
| EP-1888579-B1 | NOVEL FLUORENE DERIVATIVES, COMPOSITION CONTAINING SAID DERIVATIVES AND THE USE THEREOF | AVENTIS PHARMA SA (FR) | 2011-08-03 | — | — | EP | disclosed |
| EP-1117651-A1 | NEW BIS-BENZIMIDAZOLES | Bayer Aktiengesellschaft (DE) | 2001-07-25 | — | — | EP | disclosed |
| WO-2000020401-A1 | NEW BIS-BENZIMIDAZOLES | BAYER AKTIENGESELLSCHAFT (DE) | 2000-04-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160024085-A1 | ALKYL-HETEROARYL SUBSTITUTED QUINONE DERIVATIVES FOR TREATMENT OF OXIDATIVE STRESS DISORDERS | NQO1, COQ8A, NDUFAB1 | HSP90AA1 417/4885ESR2 1461/4885TDP1 416/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.